25 Stocks to Double

ContentsOverview 3

Sucampo Pharmaceuticals (SCMP) 4

Seattle Genetics, Inc (SGEN) 7

Infinera (INFN) 12

Meritor (MTOR) 15

Zebra Technologies (ZBRA) 19

Other Zacks Resources 22

35 Stocks to Double

OverviewThank you for your interest in Zacks and the 5 Stocks to Double report. This report will give you an idea of the enormous resources available on Zacks.com. I invite you to visit the site and get familiar with the Zacks Rank, our stock picking frame-work that has an impressive track record of generating market-beating returns year after year.

Each of the 5 stocks in this report was hand-picked by one of our stock strategists, who explain their rationale in the included stock write-ups. Clearly, this report was not written for the risk-adverse or conservative investor. Rather, these stocks are for the aggressive investor looking to add home-run potential to his or her port-folio. It would be prudent to devote no more than a small portion of your overall portfolio to these stocks.

That said, we hardly threw darts at a board to arrive at these choices. All of the stocks have catalysts that we think could fuel strong gains over the coming year. We sifted through stocks that met Zacks Rank criteria and then chose the crème de la crème. Each of the five stocks has unique qualities that make it a candidate for this report. And they are all from different sectors, offering a level of diversifi-cation even in this small sample.

Most of the stocks in this report are currently flying under the radar of most Wall Street analysts and traders, which provides a good opportunity to get in on the ground floor. The market is littered with these kinds of stocks, but only the ones with positive catalysts on the horizon burst onto the scene with monstrous gains. We made sure that we could identify specific factors that would bring these stocks out from obscurity and onto the lists of top performing stocks.

We are confident that you can realize enormous gains with these 5 stocks. Leave the singles and doubles for other portfolios; we are swinging for the fences on this one!

Best regards,

Sheraz Mian

45 Stocks to Double

Sucampo Pharmaceuticals (SCMP)When looking for a stock to double there are many things to consider. What indus-try should you look at? What does the earnings picture look like? How has the stock done recently? Using the power of the Zacks Industry Rank, Zacks Rank and some basic technical analysis you can help tip the odds in your favor.

But it’s more than that. You’ve got to find a company that’s in a growth indus-try with strong revenues that is small enough that doubling isn’t farfetched. One company that fits the criteria is small cap gem Sucampo Pharmaceuticals. Trading on the NASDAQ with ticker SCMP, Sucampo has a market cap of $600 million and is currently a Zacks Rank #1 (Strong Buy).

This global biopharmaceutical company founded in 1996 has two approved prod-ucts; AMITIZA in gastroenterology and RESCULA in ophthalmology. According to the company, recently signed partnerships for AMITIZA provide significant long-term revenues. That’s good to hear for a company that has experienced solid reve-nue growth to date. For FY2012 and FY2013, revenue grew at 48.8% and 9.95% year-over-year. Projections for this year call for another 35% on top of that.

Moving forward, Sucampo has a pipeline with mid-to-late stage assets in de-velopment. Its long-term growth strategy will include non-prostone product or company acquisitions. Prostones are a class of compounds derived from func-tional fatty acids that occur naturally in the human body. Sucampo’s previous drugs have both been derived from prostones. Diversification away from this singular source could help the company’s pipeline in the future.

55 Stocks to Double

Earnings surprises have been a big reason for the Zacks Rank #1 (Strong Buy). Sucampo has beat consensus for seven consecutive quarters. The most recent beat for Q3 2013 came in 10 cents stronger than the analysts’ estimates at 4 cents. Last quarter’s beat came on the heels of a 3 cent surprise in Q2 2014. The beat forced the hand of many analysts and saw two of them increase estimates for the current quarter, current year and next year. The bullish sentiment pushed estimates for the current quarter up from just 5 cents to 28 cents and next year jumped from 15 cents to 47 cents.

A quick look at the price and consensus chart shows the recent turnaround in consensus coupled with the turnaround in the stock price. After having several speculative spikes that took the stock higher but wasn’t backed by earnings, Sucampo stock has slowly been building a base above the $5 level. The big growth in 2015 consensus estimates versus 2014’s numbers was evident at the end of 2013. But drops in the 2015 number helped to keep the stock mild mannered. The hike in numbers was just the catalyst the stock needed in the short run to rally.

From a technical perspective the chart has looked very strong. After breaking out from an intermediate term consolidation from April to October, SCMP broke out above $7 to start this latest run. Trading well above the 25 day moving aver-age shifted by 5 days (25x5) indicates the stock is still firmly in an uptrend despite doubling off the October lows. The Commodity Channel Index (CCI) which shows the relative overbought or oversold nature of a stock indicates an overbought

65 Stocks to Double

condition since that low but it has come down in recent days as the stock has shown a consolidation just below the 52 week high at $14.38. Still, with earnings estimates jumping recently this stock could very well keep running. That’s why I’m naming it my stock to double.

75 Stocks to Double

Seattle Genetics, Inc (SGEN)Seattle Genetics, Inc. (SGEN) is a $4 billion biotechnology company focused on developing and commercializing innovative antibody-based therapies for the treatment of cancer. They are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal anti-bodies to deliver cell-killing agents directly to cancer cells.

First in a New Class of ADCsADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activ-ity.

The company’s first ADC product ADCETRIS (brentuximab vedotin) is commer-cially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. The approval of ADCETRIS makes it the first in a new class of ADCs.

Big Brother TakedaIn the biotech world, young companies rely on larger pharmaceutical enter-prises to assist with long R&D periods that require lots of funding before any FDA-approved and marketable drugs are generating income.

Seattle Genetics is jointly developing ADCETRIS in collaboration with Takeda Pharmaceutical Company. Under the collaboration, Seattle Genetics has full commercialization rights to ADCETRIS in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.

To expand on the ADCETRIS opportunity, the two companies are conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings.

85 Stocks to Double

Long-Term SurvivalIn December, Seattle Genetics and Takeda presented important research at the annual American Society of Hematology (ASH) conference in San Francisco. The partners announced four-year overall survival data from a pivotal phase II study evaluating the efficacy and safety of Adcetris for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Adcetris showed dura-ble, long-term responses in this treatment setting.

At a median follow-up in the study at 46.3 months, the four-year survival rate was estimated to be 64%, with median overall survival (OS) of 55.1 months and progres-sion-free survival (PFS) of 20 months. In other words, more than 60% of patients suffering from relapsed or refractory ALCL treated with Adcetris were alive at the fourth year of follow-up. One-third of all the patients treated in this study showed complete remission with no evidence of disease after a median follow-up of 46 months.

The company stated that historical outcomes for patients suffering from relapsed T-cell lymphoma, including systemic ALCL have shown a median OS of 5.5 months with a median PFS of 3.1 months.

Action in the Pipeline Seattle Genetics also announced detailed results from a randomized, double-blind, placebo-controlled phase III study (named AETHERA) on Adcetris for the treatment of Hodgkin lymphoma patients with the risk of disease progression following autologous stem cell transplantation (ASCT). PFS was higher in Adcetris-treated patients compared to placebo (43 months versus 24 months).

Earlier, in Sep 2014, the company had already announced that the study met its primary endpoint with a 75% improvement in PFS. Seattle Genetics intends to submit a supplemental biologics license application to the FDA for Adcetris for the above-mentioned indication in the first half of 2015.

Additionally, Seattle Genetics reported data from two ongoing phase I studies on SGN-CD19A for the treatment of B-cell malignancies including non-Hodgkin lymphoma and acute lymphoblastic leukemia. SGN-CD19A showed multiple objec-tive responses without significant myelosuppression or neuropathy. Based on this data, the company plans to initiate a randomized phase II study on SGN-CD19A for this indication in 2015.

95 Stocks to Double

A Streak of Upside Surprises While Seattle Genetics is not yet profitable, it became a Zacks #2 Rank in November because analysts were rapidly raising earnings estimates. Full-year 2014 estimates were raised from a loss of $0.82 to a loss of $0.66.

And 2015 estimates went from a loss of $0.63 to a loss of $0.51. What’s been driv-ing these revisions? Earnings surprises as you can in this table for the past four quarters...

Equally impressive is the dramatic rise in revenues as you can see below...

105 Stocks to Double

SGEN is projected to produce nearly $400 million in revenues in 2015. These trends in top and bottom line progress, in addition to the pipeline “hopes and dreams” are inspiring analysts to either reaffirm or raise their price targets for the stock. Let’s hear from some of them now.

Analysts Who See Big Potential Upside Several Wall Street analysts are positive on SGEN science and the shares, with the average price target north of $40. After the ASH conference, William Blair analysts reiterated their Outperform rating and noted...

“We reiterate our view that Seattle Genetics is well positioned, with a broad and growing pipeline, validated technology platform, and strong balance sheet ($340 million in cash). Therefore, we encourage investors to take advantage of recent share price weakness to build or add to positions.”

Jefferies analysts reiterated their $53 price target and had this to say...

“While investors have raised many concerns on competing PD-1 therapies in HL (Merck’s pembrolizumab and Bristol-Myers’ nivolumab), which demonstrated robust response rates of 66% and 87%, respectively, we believe that the recent pressure on SGEN shares is unwarranted.”

But the most bullish investment house of all is H.C. Wainwright with a $65 price target. After reviewing the company’s ASH presentation, analyst Andrew Fein concluded “Continued quality and breadth of data should yield investor re-engagement.” They see good things ahead for SGEN in 2015.

Baker Brothers Are Big Buyers Finally, one of my favorite “indicators” is institutional buying. They may not be a household name yet, but the brothers Julian and Felix Baker manage $7 billion for other institutional investors like the Tisch family, owners of the New York Giants football franchise.

The Baker Brothers bumped their stake in SGEN shares to over 20% in December.

They now hold over 25 million shares after adding nearly 1.9 million in November and almost 900k in December. These guys have used their science backgrounds to evaluate and invest in biotech companies successfully for over two decades.

115 Stocks to Double

I follow the Baker Brothers money trail often in biotech, and SGEN is now moving to the top of my buy list. As of December 15, I have no position while I watch to see if the current wave of competitive worries drops the stock to new 52-week lows under $31. I may just load the boat if it gets near the June 2013 low of $28.15.

125 Stocks to Double

Infinera (INFN)In order for a stock to double you need a few special ingredients and a whole lot of execution. In fact, stocks double all the time, some just need more time than others. In the case of Infinera (INFN) the time needed to double might be less than you think as it has the necessary ingredients.

The first and probably the most important ingredient is a combination of a grow-ing market share and overall market. This means that the company will see dramatic topline growth as their growing share of a growing market demands revenue growth.

As the provider of data to many of the world’s data centers, INFN is seeing its customer base (think total market) increase while they are seeing more customers choose or switch to their services vs competitors. As those data centers continue to increase in size, they will need a bigger pipe to allow information to flow into and out of them so those Big Data names can mine and analyze the information.

Another key ingredient to seeing a stock double is to see margins increase. This usually comes a little after the company has realized that the growth will continue even if the prices are raised. The impact of price increases, even small ones when done at scale, can have significant consequences on the bottom line. Those conse-quences are generally higher earnings, which, we believe are the primary basis for valuations.

Earnings HistoryBefore we get to the valuation, let’s take a look at the earnings history for INFN. Of the last 9 earnings reports, INFN has posted 8 beats and only one meet. That is a great sign that management is capable of guiding Wall Street to appropriate levels that can be reached and even surpassed.

The most recent report was a big one, so let’s focus on that one. The company reported EPS of $0.06, $0.04 better than the $0.02 Zacks Consensus Estimate. That translates into a 200% positive earnings surprise. The stock launched higher by more than 28% in the day following the release. But the quarter before that saw a 400% positive earnings surprise and the stock fell 2%, so what gives?

135 Stocks to Double

The company increased guidance on the late October call, telling Wall Street they expect revenue of between $175M-$185M when the consensus was calling for just under $160M. As much as this was a big increase the thing that Wall Street really likes to see is this meant the company would see sequential revenue growth. In the prior year, revenue decrease between the September and December quar-ters. The company reported $174M in the most recent quarter and is likely to show sequential growth in the upcoming quarter.

EstimatesThe result of the big beat was a big move in estimates. The Zacks Consensus Estimate moved from $0.06 to $0.15 for the current year and from $0.16 to $0.19 in the next fiscal year. The estimates for next year are likely to move much higher when the company reports earnings again as they will guide Wall Street for the coming year at that time.

ValuationSo I have painted a good picture here, so as much at the valuation might terrify you, it should be understood that many of these multiples will shrink as the company continues to execute. INFN sports a trailing PE multiple of 365x and a forward multiple of 100x. Both of those numbers make the industry average of 15x seem almost infinitely small. It isn’t until you see the INFN is expected to show revenue growth triple that of the industry and earnings growth that will be more than double the industry average does it almost make any sense.

The price to book multiple of 4x is slightly above the 3.6x industry average and the price to sales multiple of 3x is also slightly higher than the 2.3x industry aver-age. So this stock currently trades at a premium to the industry average for each metric that investors commonly look to when valuing an investment. Still, the overwhelming idea here is growth, and INFN will likely growth into the valuation and the metrics will, in time, shrink to more appropriate levels.

145 Stocks to Double

155 Stocks to Double

Meritor (MTOR)Meritor offers investors attractive upside potential. This small cap stock has deliv-ered big surprises for several quarters in a row as it seeks to accomplish the finan-cial targets set forth in its M2016 plan. Analysts have revised their earnings esti-mates significantly higher for Meritor too, sending the stock to a Zacks Rank of 2 (Buy).

While shares have soared recently, the valuation picture still looks attractive with the stock trading at just 10x forward earnings and 0.4x sales.

About MeritorMeritor, Inc. supplies drivetrain, mobility, braking and aftermarket solutions for commercial vehicle and industrial markets. Its primary products are axles, under-carriages, drivelines, brakes and braking systems. The company serves commercial truck, trailer, military, bus and coach, construction, and other industrial OEMs and certain aftermarkets.

Sales from outside of North America accounted for approximately 42% of total sales in fiscal year 2014. Meritor is headquartered in Troy, Michigan.

Meritor reports its results in two segments:

• Commercial Truck & Industrial (76% of total sales in fiscal 2014). This segment supplies drivetrain systems and components, including axles, drivelines and braking and suspension systems, for medium- and heavy-duty trucks, off-highway, military, construction, bus and coach, fire and emergency and other applications. This segment also includes the company’s aftermarket businesses in Asia-Pacific and South America.

• Aftermarket & Trailer (24% of total sales in fiscal 2014). This segment supplies axles, brakes, drivelines, suspension parts and other replacement and reman-ufactured parts to commercial vehicle aftermarket customers in North America and Europe. This segment also supplies a wide variety of undercar-riage products and systems for trailer applications in North America.

165 Stocks to Double

The sales breakdown by product category in 2014 was as follows:

• Axles, Undercarriage and Drivelines: 78%

• Brakes & Braking Systems: 21%

• Other: 1%

M2016 Plan• In 2013, Meritor launched M2016, which is a three-year plan aimed at improv-

ing the EBITDA (earnings before interest, taxes, depreciation and amorti-zation) margin, reducing debt (including retirement liabilities) and increas-ing revenue through organic growth. It set the following specific financial measures for fiscal 2016:

• Adjusted EBITDA of 10%

• Reduce net debt, including retirement benefit liabilities, by $400 million to < $1.5 billion, and

• Incremental booked revenue of $500 million per year

• The company already achieved its net debt target, thanks in part to a $208 million favorable legal settlement with Eaton. In fiscal 2014, the adjusted EBITDA margin was 8.3%, up from 7.2% in fiscal 2013, due in large part to strong cost controls. Management believes it can get to 10% in fiscal 2016 by reducing product costs, driving operational excellence and through new business wins and an improving industry.

Estimates RisingMertior has delivered an impressive seven consecutive positive earnings surprises, including a whopping 119% EPS beat on November 12. This prompted analysts to revise their estimates significantly higher for both fiscal 2015 and fiscal 2016, send-ing the stock to a Zacks Rank of 2 (Buy).

175 Stocks to Double

The 2015 Zacks Consensus Estimate increased from $1.09 before the fiscal 2014 Q4 report to $1.36. The 2016 estimates jumped from $1.32 to $1.63 over the same period.

Based on these consensus estimates, analysts are projecting 33% EPS growth for the company in fiscal 2015 and 20% growth in 2016.

Valuation & RisksShares of Meritor have been soaring lately, but the valuation picture still looks attractive. The stock trades at just 10x 12-month forward earnings, a discount to the industry median of 13x. And its price to sales ratio of 0.4 is also below the industry multiple of 0.8.

If the company can continue to deliver positive surprises, the market should gain confidence in its ability to meet those M2016 financial targets, which could lead to meaningful expansion in those valuation multiples.

There are a few risks to be aware of with Meritor, however.

185 Stocks to Double

First, the company’s financial results are heavily dependent on the global econ-omy. This also means that the stock price is highly volatile relative to the overall market. Additionally, 27% of total sales in fiscal 2014 came from just three custom-ers: AB Volvo, Daimler AG and Navistar International Corporation. Not only does this give these customers pricing power, but the loss of one of these customers would materially impact sales and profits. And while the company has taken steps to lower its debt burden, it is still highly leveraged.

The Bottom LineOverall, the outlook for Meritor looks bright. The company is delivering on the ambitious goals set forth in its M2016 plan, earnings estimates are soaring, and the valuation picture looks attractive.

195 Stocks to Double

Zebra Technologies (ZBRA)As the world is becoming more connected, businesses need more products and solutions that provide them with real-time insights into their assets and processes and help them make more informed decisions. Companies that provide such enabling technologies have strong growth potential in the coming years.

Zebra Technologies (ZBRA) is a leading global manufacturer of specialty printers, scanners, RFID and location & motion tracking services that are used by businesses for identifying, tracking and managing important assets. The company has the largest installed base of thermal printers in the industry. Their portfolio of mark-ing and printing technologies including Radio Frequency Identification (RFID) and Real Time Location solutions that help business improve their processes.

Founded in 1969 and headquarter in Lincolnshire, IL, the company now has approx-imately 7,100 employees in more than 122 offices across 81 countries.

In 2013, 44% of the sales were in North America, followed by 34% in Europe, Middle East & Africa and 15% in Asia Pacific. Retail, Transportation & Logistics, Manufacturing and Healthcare are the top industries the company supplies its products and services to.

Excellent Third Quarter ResultsThe company reported its Q3 2014 results on November 4. Sales jumped to $303 million, up 15.1% from Q3 of 2013, with growth across all regions and multiple product lines. High pipeline activity generated many large deals in key industries. Three out of four geographic reporting regions recorded double digit growth, with 16% growth in North America, where they had a surge in shipments ahead of the holiday season.

Gross margin expanded by 1.2% to 50.0%. Margin expansion was thanks mainly to the higher product volume and lower inbound freight cost. Adjusted net income for the quarter was $0.93 per share, ahead of the Zacks Consensus Estimate of $0.85 per share and also above the management’s guidance range.

205 Stocks to Double

The company has an excellent record of delivering positive surprises, as can be seen from the following chart:

The company also provided their guidance for the current quarter; they expect sales in the range of $300 million to $310 million, up 7% from a year ago. The mid-point of this guidance range translates into a sales growth of 14% for the full year. The balance sheet remained with strong, with no long-term debt and $542 million in cash and short term investments.

On October 27, Zebra completed the acquisition of Motorola Solution’s Enterprise business for $3.45 billion in cash. According to the management, this business is a strategic fit for Zebra as it “significantly expands and strengthens Zebra’s prod-uct portfolio, geographic reach, go-to-market channels and industries served. The combined organization has about 20,000 channel partners in more than 100 coun-tries, and approximately 4,300 US and international patents issued and pending.”

Estimates RisingThanks to excellent results and guidance, analysts have revised their estimates for the company. Zacks Consensus Estimates for 2014 and 2015 are currently $3.90 per share and $5.68 per share, compared with $3.51 per share and $4.20 per share respectively, 60 days ago.

Rising estimates sent the stock to a Zacks Rank #1 (Strong Buy) last month. The

215 Stocks to Double

following chart shows the positive earning momentum for the stock.

The Bottom Line

In order to meet customers’’ evolving needs, Zebra continues to invest in emerg-ing technology trends and new products development. Zebra’s products and solu-tions provide businesses greater real-time insights into location and movements of their assets and people and help them improve their business processes and make smarter decisions.

With continued focus on innovation and great diversity of product lines, chan-nels and geographies, Zebra looks well poised to capitalize on emerging growth trends in e-commerce and technology..

225 Stocks to Double

Other Zacks ResourcesZacks.com is the one place dedicated to helping individual investors profit from the pros with resources like:

Zacks.comThis is our free web site that offers the following powerful features.

• Zacks Profit from the Pros. Zacks Profit from the Pros. Delivered five times a week – every trading day – this email provides the easiest way for you to get a wealth of independent research and stock ideas. Plus, you’ll receive our Weekend Wisdom issue each Saturday. You’ll also receive expert commen-tary, top stock picks, winning stock screens, and more. If you received this special report, then you are already set up as a Profit from the Pros subscriber. Now stay tuned to your inbox to receive these critical updates. See the current issue.

• Portfolio Tracker. Manage your portfolio on Zacks.com, and we’ll send you daily alerts of any changes affecting your stocks. Sign up.

• Screening. Access more stock screening capabilities with our pre-defined screens and custom screener. Learn more...

• Analyst Blogs. Get the latest news and analysis on key stocks, industries, and the markets with our Analyst Blogs. See the latest blog.

• Industry. See what industries are hot or not. Keep your eye out to know industry developments and how they affect your stocks. Read our Industry Rank articles.

Zacks UltimateZacks is unlocking the Vault, allowing full access to our most coveted secrets. This opportunity reveals Zacks’ exclusive stock picks and insights, from trading services that, produce scores of double-digit winners, even in volatile markets. Learn more...

Zacks ConfidentialWith his service, Steve Reitmeister takes you “behind the scenes.” Each week, he spotlights one of our experts who is about to trigger the most compelling trades

235 Stocks to Double

to beat the current market. He will confide to you that strategist’s best insights, buys and sells — information not available to the public. Learn more...

Zacks PremiumOur premier subscription service that provides Zacks proprietary research. It’s the same research that leading Wall Street brokerage firms pay millions of dollars for each year – but at a low price just for individual investors.

• Zacks Rank. This is the cornerstone and foundation of all of Zacks indepen-dent research. With an uncanny ability to predict stocks likely to beat the market within 90 days, the Zacks Rank #1 (Strong Buy) stocks boast a 26% average annual return since 1986. Conversely, the Zacks Rank #5 (Strong Sell) stocks have been outpaced by the S&P 500 by 90% in that same time. Learn more...

• Zacks Equity Research and Recommendations. Gain proven long-term recommendations and in-depth research with proven cumulative return of 475% since 2003, handily beating the market. Learn more...

• Custom Screening and Email Alerts with the Zacks Rank. Use your favor-ite screens but add the power of the Zacks Rank. Learn immediately when the Zacks Rank of your portfolio’sE stocks changes so you can take quick action. It’s only available and all included in Zacks Premium. Learn more...

ETF TraderTo find “Hidden Bulls,” this portfolio uses the Zacks Industry Rank with its 2-to-1 performance advantage, the Zacks ETF Rank, and other factors. Then it rides the emerging trends through selected Exchange Traded Funds – without added risk and fees from buying stocks individually. Learn more...

Follow the Money TraderUncovers the stocks bought and sold by the institutions in the mountains of their regulated 13D and 13G filings. With such large institutional positions, these stocks are likely to soar once the market catches on. Learn more...

Home Run InvestorZacks’ long-term investor service targets under-the-radar companies with over-

245 Stocks to Double

the-top +50% or +100% potential. But it’s ever watchful to prevent strike-outs by cutting losers and providing diversity. The key is pinpointing strong Zacks Rank companies with potential to grow past the normal one-to-three-month profit zone. Learn more...

Income Plus InvestorZacks introduces a new approach to income investing. It’s designed to balance more aggressive moves with a steady flow of income. Selected high dividend stocks plus other low-risk assets replace fixed-income investments that lose to inflation. Learn more...

Insider TraderThis service follows officers, directors and substantial owners who have just dug deep into their own pockets to make stock purchases in their own companies. Then it filters the stock through the Zacks Rank timeliness and valuation factors to find a handful with potential for the most extreme price gains. Learn more...

International TraderWhy restrict your profit search to the U.S., which generates less than 22% of the world’s GDP? Directed by Chief Equity Strategist John Blank, Ph.D., this service offers extreme upside potential and protection against domestic downturns. It rides tailwinds of stock valuation discounts and booming economies relative to the U.S. with selected ADRs and ETFs for stocks, bonds, currencies, and more. Learn more...

Market TimerSmall market swings, up or down, can lead to big profits. The new Zacks Market Timer detects early signals through technical patterns, investor sentiment, global macro trends, and Zacks Rank data. Then it uses leveraged ETFs to multiply gain potential. Learn more...

Options TraderKevin Matras infuses options trading with the +26% yearly gain power of the Zacks Rank plus his own market-beating stock screens. This creates the potential for steady and substantial returns using only a fraction of the money you would have risked on regular stock purchases. Learn more...

255 Stocks to Double

Reitmeister Trading Alert The Reitmeister Trading Alert is Zacks’ answer to today’s volatile market. It uses the power of the Zacks Rank, combined with value trading and a dash of market timing, to generate profits no matter what the market has to offer. Learn more...

Research WizardThis powerful screening and backtesting software puts you in control of your investment strategy. Use the same tool professional stock pickers use to find winning stocks in any market. Learn more...

Surprise TraderZacks’ research breakthrough isolates the most accurate analyst “whispers” to detect positive earnings surprises before they’re reported. The strategy’s tested accuracy is an unprecedented 77.32%. When alerted to “surprise stocks” before Wall Street can react to them, you can fully ride their price pops. Learn more...

Top 10 Stocks This annual stock portfolio provides the best group of 10 stocks to invest in during the year. The list is announced in January each year. We start with the Zacks Recommendation - a market-crushing measurement for long-term success - and use a nine-step process to hand-pick the 10 stocks you should buy and hold all year for effortless profits. Click here for the 2015 edition.

Value Investor This long-term service combines value criteria with Zacks Rank timing. We’ll track undervalued companies until the market starts to see their real worth. Then we’ll “pounce” for gains that can build for years. Learn more...

Zacks Method for Trading Learn how to use the Zacks Rank even more effectively than professional fund managers, with simple step-by-step instruction. Learn more...

The return numbers presented assume no transaction costs. Details of how Zacks calculates performance for the Zacks Rank Portfolios and strategies is available at: http://www.zacks.com/performance.